Covetrus Stock Forecast, Price & News

-0.55 (-1.88 %)
(As of 04/9/2021 12:00 AM ET)
Today's Range
Now: $28.74
50-Day Range
MA: $32.32
52-Week Range
Now: $28.74
Volume616,587 shs
Average Volume823,748 shs
Market Capitalization$3.92 billion
P/E RatioN/A
Dividend YieldN/A
Covetrus, Inc., together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, and vitamins and supplements to wholesale and retail customers. The company also offers value-added practice solutions that include financial services, equipment repair, inventory management, and e-commerce, as well as continuing education services for practitioners. In addition, it provides practice management software systems for veterinary practitioners and animal-health clinics, client communication services, reminders, data backup services, and hardware sales and support services. Further, the company engages in the distribution of finished goods pharmacy and specialty pharmaceutical compounding products, as well as e-commerce, shipping, manufacturer incentives, service fees, and data integration and support services. It serves animal-health and veterinary practices, and clinics in the companion-animal and equine markets primarily in North America, Europe, and the Asia Pacific. The company, formerly known as HS Spinco, Inc., was incorporated in 2018 and is headquartered in Portland, Maine.
Covetrus logo

Industry, Sector and Symbol

Industry Drug stores & proprietary stores
Current SymbolNASDAQ:CVET
Year FoundedN/A



Sales & Book Value

Annual Sales$3.98 billion
Cash Flow$8.35 per share
Book Value$11.20 per share


Net Income$-1,019,000,000.00


Market Cap$3.92 billion
Next Earnings Date5/13/2021 (Estimated)
OptionableNot Optionable


Boehringer Ingelheim Adopts Veeva's (VEEV) CRM Solution
March 25, 2021 |
Covetrus (NASDAQ:CVET) Shares Down 8.1%
March 16, 2021 |
Covetrus: 4Q Earnings Snapshot - Yahoo Finance
March 1, 2021 |
See More Headlines


Overall MarketRank

1.60 out of 5 stars

Computer And Technology Sector

265th out of 1,542 stocks

Drug Stores & Proprietary Stores Industry

3rd out of 14 stocks

Analyst Opinion: 2.4Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
-0.55 (-1.88 %)
(As of 04/9/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CVET News and Ratings via Email

Sign-up to receive the latest news and ratings for CVET and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Covetrus (NASDAQ:CVET) Frequently Asked Questions

Is Covetrus a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Covetrus in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Covetrus stock.
View analyst ratings for Covetrus
or view top-rated stocks.

What stocks does MarketBeat like better than Covetrus?

Wall Street analysts have given Covetrus a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Covetrus wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Covetrus' next earnings date?

Covetrus is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for Covetrus

How were Covetrus' earnings last quarter?

Covetrus, Inc. (NASDAQ:CVET) posted its quarterly earnings results on Sunday, February, 28th. The company reported $0.21 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.16 by $0.05. The business earned $1.12 billion during the quarter, compared to analysts' expectations of $1.06 billion. Covetrus had a negative net margin of 1.21% and a positive trailing twelve-month return on equity of 7.09%. Covetrus's revenue was up 11.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.18 EPS.
View Covetrus' earnings history

How has Covetrus' stock price been impacted by COVID-19 (Coronavirus)?

Covetrus' stock was trading at $9.04 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CVET stock has increased by 217.9% and is now trading at $28.74.
View which stocks have been most impacted by COVID-19

What price target have analysts set for CVET?

4 brokerages have issued 12-month target prices for Covetrus' shares. Their forecasts range from $20.00 to $48.00. On average, they anticipate Covetrus' stock price to reach $33.25 in the next year. This suggests a possible upside of 15.7% from the stock's current price.
View analysts' price targets for Covetrus
or view top-rated stocks among Wall Street analysts.

Who are Covetrus' key executives?

Covetrus' management team includes the following people:
  • Mr. Benjamin Wolin, CEO, Pres & Director (Age 45, Pay $1.03M)
  • Mr. Dustin k. Finer, Chief Admin. Officer (Age 51, Pay $552.6k)
  • Ms. Georgina Wraight, Exec. VP & Pres of Global Technology Solutions (Age 46, Pay $623.24k)
  • Mr. Matthew J. Foulston, Global Chief Financial Officer (Age 56)
  • Ms. Laura J. Phillips, VP, Chief Accounting Officer & Global Controller (Age 51)
  • Mr. Steve Palmucci, Global Chief Information Officer
  • Mr. Nicholas Michael Jansen, VP of Investor Relations
  • Ms. Jamey S. Seely, Gen. Counsel & Corp. Sec. (Age 49)
  • Kiní Schoop, Director of PR
  • Mr. Anthony C. Providenti Jr., Exec. VP of Corp. Devel. (Age 54)

What is Benjamin Wolin's approval rating as Covetrus' CEO?

25 employees have rated Covetrus CEO Benjamin Wolin on Benjamin Wolin has an approval rating of 89% among Covetrus' employees.

Who are some of Covetrus' key competitors?

What other stocks do shareholders of Covetrus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Covetrus investors own include Pfizer (PFE), NVIDIA (NVDA), Advanced Micro Devices (AMD), AT&T (T), Activision Blizzard (ATVI), The Boeing (BA), Chegg (CHGG), Enphase Energy (ENPH), Enterprise Products Partners (EPD) and Livongo Health (LVGO).

What is Covetrus' stock symbol?

Covetrus trades on the NASDAQ under the ticker symbol "CVET."

Who are Covetrus' major shareholders?

Covetrus' stock is owned by a number of institutional and retail investors. Top institutional shareholders include State of Alaska Department of Revenue (0.05%) and Everence Capital Management Inc. (0.01%). Company insiders that own Covetrus stock include Anthony C Jr Providenti, Benjamin Shaw, Benjamin Wolin, Betsy S Atkins, David Christopher Dollar, David Stuart Hinton, Dustin Finer, Edward Mcnamara, Erin Powers Brennan, Georgina Wraight, Michael Ellis and Timothy Ludlow.
View institutional ownership trends for Covetrus

Which institutional investors are selling Covetrus stock?

CVET stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have sold Covetrus company stock in the last year include Anthony C Jr Providenti, Benjamin Wolin, David Stuart Hinton, Dustin Finer, Edward Mcnamara, Georgina Wraight, Michael Ellis, and Timothy Ludlow.
View insider buying and selling activity for Covetrus
or view top insider-selling stocks.

Which institutional investors are buying Covetrus stock?

CVET stock was bought by a variety of institutional investors in the last quarter, including Everence Capital Management Inc.. Company insiders that have bought Covetrus stock in the last two years include Benjamin Shaw, and Erin Powers Brennan.
View insider buying and selling activity for Covetrus
or or view top insider-buying stocks.

How do I buy shares of Covetrus?

Shares of CVET can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Covetrus' stock price today?

One share of CVET stock can currently be purchased for approximately $28.74.

How much money does Covetrus make?

Covetrus has a market capitalization of $3.92 billion and generates $3.98 billion in revenue each year. The company earns $-1,019,000,000.00 in net income (profit) each year or $0.79 on an earnings per share basis.

How many employees does Covetrus have?

Covetrus employs 5,100 workers across the globe.

What is Covetrus' official website?

The official website for Covetrus is

Where are Covetrus' headquarters?

Covetrus is headquartered at 7 CUSTOM HOUSE STREET, PORTLAND ME, 04101.

How can I contact Covetrus?

Covetrus' mailing address is 7 CUSTOM HOUSE STREET, PORTLAND ME, 04101. The company can be reached via phone at 888-280-2221 or via email at [email protected]

This page was last updated on 4/10/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.